Herantis Pharma has announced positive FDA feedback and finalised the Phase IIa design for HER-096 in Parkinson’s disease (PD). Following a pre-IND meeting, the FDA raised no concerns on the preclinical package, confirmed that current data would support activation of US clinical sites if an IND is
